Skip to main content
logo
Lexeo Therapeutics, Inc. (LXEO)
NASDAQ: LXEO · Real-Time Price · USD
5.14
+0.06 (1.18%)
At close: May 29, 2026, 4:00 PM EDT
5.15
+0.01 (0.19%)
After-hours: May 29, 2026, 5:57 PM EDT

Lexeo Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
----0.651.66
Revenue Growth (YoY)
-----60.53%219.59%
Gross Profit
----0.651.66
Selling, General & Admin
35.4645.4631.6815.38127.17
Research & Development
62.3363.874.0953.1349.1645.12
Total Operating Expenses
97.79109.26105.7768.5161.1652.29
Operating Income
-97.79-109.26-105.77-68.51-60.51-50.64
Interest Income
7.096.027.582.871.330.02
Interest Expense
-0.08-0.1-0.14-0.21-0.09-
Other Non-Operating Income (Expense)
3.283.37-0.01-0.54-0-
Total Non-Operating Income (Expense)
10.289.37.432.121.230.02
Pretax Income
-87.5-99.96-98.33-66.39-59.28-50.62
Net Income
-87.5-99.96-98.33-66.39-59.28-50.62
Net Income to Common
-87.5-99.96-98.33-66.39-59.28-50.62
Shares Outstanding (Basic)
665432522
Shares Outstanding (Diluted)
665432522
Shares Change (YoY)
98.17%68.76%493.67%228.42%5.00%7.72%
EPS (Basic)
-1.45-1.86-3.09-12.40-36.36-32.60
EPS (Diluted)
-1.45-1.86-3.09-12.40-36.36-32.60
Shares Outstanding
74.097333.0726.651.611.58
Free Cash Flow
-98.42-98.96-81.63-59.61-55.23-44.37
Free Cash Flow Per Share
-1.50-1.84-2.57-11.13-33.88-28.58
Gross Margin
----100.00%100.00%
Operating Margin
-----9252.14%-3055.94%
Profit Margin
-----9063.76%-3055.04%
FCF Margin
-----8445.26%-2677.73%
EBITDA
-97.5-108.99-105.46-68.24-60.39-50.62
EBITDA Margin
-----9233.79%-3055.16%
EBIT
-97.79-109.26-105.77-68.51-60.51-50.64
EBIT Margin
-----9252.14%-3055.94%
SEC Filings: 10-K · 10-Q